DELCATH SYSTEMS, INC.
Close on Oct 19, 2026
- Market cap
- $571.37M
- P/E (TTM)
- 1437.0
- Dividend yield
- –
Earnings
Next report expected Oct 19, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $29.10M | $0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $25.00M | $-0.03 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | After market close | $20.70M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 20, 2025 | Before market open | $20.50M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $24.20M | $0.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $19.80M | $0.03 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | $15.10M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 17, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | $7.80M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Full year gross margins | Full year | 86% to 89% | Raised |
| Total HEPZATO KIT and CHEMOSAT revenue | fiscal year 2026 | $104.00M to $108.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Delcath Systems filed with the SEC
Delcath Systems Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Reports First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces Publication of
Other events · EX-99.1 to Form 8-K
Delcath Systems Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Forward-Looking Statement alternative indications; the impact of the
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Delcath Systems Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Delcath Systems Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Issues Full Year 2025 Guidance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delcath Systems Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Forward-Looking Statement The Private Securities Litigation Reform Act
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Delcath Systems Announces Additional $16.3 Million in Funding
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
Results of operations · Other events · EX-99.1 to Form 8-K
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver
Other events · EX-99.1 to Form 8-K
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma
Other events · EX-99.2 to Form 8-K
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces $7 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Delcath Systems Receives Permanent J-Code (J9248) for
Other events · EX-99.1 to Form 8-K
Table of Contents Forward-Looking Statement 3 Investment Summary 4 Unmet
Regulation FD disclosure · EX-99.1 to Form 8-K
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
September 6, 2023 1 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Other events · EX-99.1 to Form 8-K
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Delcath Systems Announces up to $85 Million Financing
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Delcath Systems Announces Closing of Private Placement of up to $85 Million
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Delcath Systems Announces up to $85 Million Financing
Results of operations · EX-99.1 to Form 8-K